"10.1371_journal.pone.0144004","plos one","2015-12-09T00:00:00Z","Tarik Asselah; Stefan Zeuzem; Vicente Soriano; Jean-Pierre Bronowicki; Ansgar W Lohse; Beat Müllhaupt; Marcus Schuchmann; Marc Bourlière; Maria Buti; Stuart K Roberts; Edward J Gane; Jerry O Stern; Florian Voss; Patrick Baum; John-Paul Gallivan; Wulf O Böcher; Federico J Mensa","Service d’Hépatologie, Hôpital Beaujon, INSERM UMR S 1149, CRI, Université Paris Diderot, DHU UNITY, Clichy, France; J. W. Goethe University Hospital, Frankfurt, Germany; Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain; INSERM U954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France; I. Medizinische Klinik und Poliklinik, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland; Department of Internal Medicine I, University Hospital Mainz, Mainz, Germany; Service d’hépato-gastro-entérologie, Hôpital Saint Joseph, Marseille, France; Liver Unit, Hospital Universitario Valle de Hebron and CIBERehd del Instituto Carlos III, Barcelona, Spain; Department of Gastroenterology, Alfred Hospital, Melbourne, Australia; Auckland Clinical Studies, Auckland, New Zealand; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States of America; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany","Conceived and designed the experiments: TA JOS FV PB J-PG WOB FJM. Performed the experiments: TA SZ VS J-PB AWL BM MS M. Bourlière M. Buti SKR EJG. Analyzed the data: TA SZ VS J-PB AWL BM MS M. Bourlière M. Buti SKR EJG JOS FV PB J-PG WOB FJM. Wrote the paper: TA SZ VS J-PB AWL BM MS M. Bourlière M. Buti SKR EJG JOS FV PB J-PG WOB FJM. Study investigators and contributed to recruitment of patients: TA SZ VS J-PB AWL BM MS M. Bourlière M. Buti SKR EJG. Contributed to data collection: TA SZ VS J-PB AWL BM MS M. Bourlière M. Buti SKR EJG. Conduction of statistical analysis: FV PB.","TA has received consultancy fees from BMS, Boehringer Ingelheim, Roche, Merck-Schering Plough, Gilead, and Janssen. SZ has received consultancy fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Idenix, Janssen, Merck, Novartis, Presidio, Roche, Santaris, and Vertex. VS has received grant support from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, and Merck, has served on speaker bureaus for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, and Merck, and has received compensation for educational presentations from Gilead, Janssen, Merck, and ViiV. J-PB has received consultancy fees from Boehringer Ingelheim, BMS, Gilead, Janssen, MSD, and Novartis, and has received speaker fees from BMS, Gilead, Janssen, MSD, and Roche. AWL has received grant support from Boehringer Ingelheim, BMS, Falk, Gilead, MSD and Roche. BM has received grant support from MSD and Roche and is an advisor for Gilead, Janssen, MSD, and Roche. MS has received consultancy fees and speaker honoraria from Roche, Gilead, BMS, Merck, Boehringer Ingelheim, Janssen and Falk. M. Bourlière has served on advisory boards for Boehringer Ingelheim, Merck, Vertex, Janssen, Gilead, Abbott, GSK and Roche, and has also received lecture fees from Merck, Janssen, Boehringer Ingelheim, and Gilead. M. Buti has served as consultant for Boehringer Ingelheim, and has received payment for lectures from BMS, Gilead, Janssen, MSD, and Novartis. SKR is a consultant for BMS, Gilead, Janssen, and Roche. EJG is member of advisory boards for Abbot, Gilead, Janssen, Roche, and Tibotec. He has received speaker fees for Gilead, Janssen, AbbVie, Novartis, and Roche. JOS, FV, PB, J-PG, WOB, and FJM are employees of Boehringer Ingelheim. These commercial affiliations do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.","2015","12","Tarik Asselah","TA",17,TRUE,7,8,8,8,TRUE,TRUE,TRUE,2,"10;11",TRUE
